CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
NCT02189629
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
453
Enrollment
INDUSTRY
Sponsor class
Conditions
Acne Vulgaris
Interventions
DRUG:
CD5789 (trifarotene)
Sponsor
Galderma R&D